BIOAGE LABS, INC. (BIOA) Free cash flow
- Free cash flow · 12 months (USD): Value $-88.09M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -850.69%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-88.09M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-87.60M − $488.00K ≈ $-88.09M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -850.69% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-88.09M ÷ $10.36M × 100 ≈ -850.69% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-87.60M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.93× | Operating cash flow / net income. Period ending 2026-06-30. $-87.60M ÷ $-94.46M ≈ 0.93× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -87.60M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 488.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -88.09M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 10.36M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -94.46M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-88.09M | (m) | $-87.60M | $488.00K | (m) | $10.36M | (m) | $-94.46M | (m) | (m) | -850.69% | 0.93× |
| 2026-03-31 | $-88.63M | (m) | $-88.31M | $319.00K | (m) | $10.32M | (m) | $-89.93M | (m) | (m) | -859.14% | 0.98× |
| 2025-12-31 | $-82.35M | (m) | $-81.63M | $719.00K | (m) | $8.99M | (m) | $-80.61M | (m) | (m) | -915.46% | 1.01× |
| 2025-09-30 | $-59.15M | (m) | $-58.51M | $633.00K | (m) | (m) | (m) | $-75.79M | (m) | (m) | (m) | 0.77× |
| 2025-06-30 | $-58.32M | (m) | $-57.40M | $916.00K | (m) | (m) | (m) | $-79.03M | (m) | (m) | (m) | 0.73× |
| 2025-03-31 | $-54.01M | (m) | $-53.21M | $792.00K | (m) | (m) | (m) | $-71.05M | (m) | (m) | (m) | 0.75× |
| 2024-12-31 | $-51.89M | (m) | $-51.52M | $366.00K | (m) | (m) | (m) | $-71.11M | (m) | (m) | (m) | 0.72× |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-65.76M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-37.53M | (m) | $-37.36M | $166.00K | (m) | (m) | (m) | $-63.85M | (m) | (m) | (m) | 0.59× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |